Drug Trial Radar · NCT07434050
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Jun 19, 2028
Study completion Jun 19, 2028
Sponsor
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
Conditions
- OSA - Obstructive Sleep Apnea
- Obesity
Interventions
XW003 injectionDrug
subcutaneous injection
placebo with matching volumeDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Apnea-Hypopnea Index (AHI)Time frame: at week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rui Jin Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.